These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30753289)

  • 21. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
    Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
    Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
    Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 28. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
    Garitano-Trojaola A; Sancho A; Götz R; Eiring P; Walz S; Jetani H; Gil-Pulido J; Da Via MC; Teufel E; Rhodes N; Haertle L; Arellano-Viera E; Tibes R; Rosenwald A; Rasche L; Hudecek M; Sauer M; Groll J; Einsele H; Kraus S; Kortüm MK
    Commun Biol; 2021 Jun; 4(1):799. PubMed ID: 34172833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang ES
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.
    Levis MJ
    Clin Adv Hematol Oncol; 2019 Jun; 17(6):323-325. PubMed ID: 31437132
    [No Abstract]   [Full Text] [Related]  

  • 34. Midostaurin + Chemo Ups AML Survival.
    Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment practice and outcomes in
    Chua CC; Grigg A; Singh J; Droogleever MP; Zhang L; Lim A; Fong CY; Ting SB; Schwarer A; Tiong IS; Wei AH
    Leuk Lymphoma; 2020 Apr; 61(4):848-854. PubMed ID: 31752581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
    Fathi AT; Chabner BA
    Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France.
    Tremblay G; Cariou C; Recher C; Dolph M; Brandt P; Blanc AS; Forsythe A
    Eur J Health Econ; 2020 Jun; 21(4):543-555. PubMed ID: 31970530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
    Stone RM; Fischer T; Paquette R; Schiller G; Schiffer CA; Ehninger G; Cortes J; Kantarjian HM; DeAngelo DJ; Huntsman-Labed A; Dutreix C; del Corral A; Giles F
    Leukemia; 2012 Sep; 26(9):2061-8. PubMed ID: 22627678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
    Dotson J; Elhamdani A; Petryna E; Jamil MO; Alsharedi M
    Int J Hematol; 2019 Mar; 109(3):351-355. PubMed ID: 30506467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Patnaik MM
    Leuk Lymphoma; 2018 Oct; 59(10):2273-2286. PubMed ID: 29164965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.